Targeting TKI-resistance in NSCLC: Importance of rebiopsy and molecular diagnostics-A case study

Cancer Treatment Communications

Volumn 1, Issue 1, 2013, Pages 1-5

  Stoehlmacher Williams, Jan ^a   Ehninger, Gerhard ^a   Zimmermann, Dieter R ^b   Merkelbach Bruse, Sabine ^c   Schildhaus, Hans Ulrich ^c   Buettner, Reinhard ^c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Afatinib; EGFR TKI; Fifth line; NSCLC; Rebiopsy; Secondary resistance

Indexed keywords

AFATINIB; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GEMCITABINE; MITOXANTRONE; ONCOPROTEIN; PACLITAXEL; PEMETREXED; PHOSPHOTRANSFERASE INHIBITOR;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BRAIN METASTASIS; BRAIN RADIATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DYSPNEA; FEMALE; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MOLECULAR DIAGNOSTICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; POINT MUTATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RASH; THORAX PAIN; TINNITUS;

EID: 84888125343     PISSN: 22130896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrc.2013.07.001     Document Type: Article

References (16)

1. Pfister D.G., Johnson D.H., Azzoli C.G., et al. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. Journal of Clinical Oncology 2004, 22(2):330-353.
2. Dienstmann R., Martinez P., Felip E. Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget 2011, 2(3):165-177.
3. Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLOS Medicine 2005, 3:e73.
4. Solca F., Dahl G., Zoephel A., et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. Journal of Pharmacology and Experimental Therapeutics 2012, 343(2):342-350.
5. Sequist L.V., Waltman B.A., Dias-Santagata D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science Translational Medicine 2011, 3(75):75ra:26.
6. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer 2007, 7(3):169-181.
7. Rosell R., Molina-Vila M.A., Taron M., et al. EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study. Journal of Clinical Oncology 2012, 30(15). (Suppl: abstr. 7522).
8. Rosell R., Molina M.A., Costa C., et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clinical Cancer Research 2011, 17(5):1160-1168.
9. Su K.Y., Chen H.Y., Li K.C., et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. Journal of Clinical Oncology 2012, 30(4):433-440.
10. Yun C.H., Mengwasser K.E., Toms A.V., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(6):2070-2075.
11. Li D., Ambrogio L., Shimamura T., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27(34):4702-4711.
12. Wong M.K., Lo A.I., Lam B., Lam W.K., Ip M.S., Ho J.C. Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 2010, 65(6):1023-1028.
13. Takezawa K., Pirazzoli V., Arcila M.E., et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discovery 2012, 10:922-933.
14. Riely G.J., Chmielecki J., Kris M.G., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clinical Cancer Research 2011, 17(6):1616-1622.
15. Miller V.A., Hirsh V., Cadranel J., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncology 2012, 13(5):528-538.
16. Hirsh V., Cadranel J., Cong X.J., et al. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). Journal of Thoracic Oncology 2013, 8(2):229-237.